1. Home
  2. SRRK vs KFY Comparison

SRRK vs KFY Comparison

Compare SRRK & KFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • KFY
  • Stock Information
  • Founded
  • SRRK 2012
  • KFY 1969
  • Country
  • SRRK United States
  • KFY United States
  • Employees
  • SRRK N/A
  • KFY N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • KFY Diversified Commercial Services
  • Sector
  • SRRK Health Care
  • KFY Consumer Discretionary
  • Exchange
  • SRRK Nasdaq
  • KFY Nasdaq
  • Market Cap
  • SRRK 4.2B
  • KFY 3.5B
  • IPO Year
  • SRRK 2018
  • KFY 1999
  • Fundamental
  • Price
  • SRRK $43.12
  • KFY $70.75
  • Analyst Decision
  • SRRK Strong Buy
  • KFY Buy
  • Analyst Count
  • SRRK 7
  • KFY 4
  • Target Price
  • SRRK $40.43
  • KFY $77.00
  • AVG Volume (30 Days)
  • SRRK 1.1M
  • KFY 349.2K
  • Earning Date
  • SRRK 11-12-2024
  • KFY 03-05-2025
  • Dividend Yield
  • SRRK N/A
  • KFY 2.04%
  • EPS Growth
  • SRRK N/A
  • KFY 137.12
  • EPS
  • SRRK N/A
  • KFY 4.67
  • Revenue
  • SRRK N/A
  • KFY $2,708,790,000.00
  • Revenue This Year
  • SRRK N/A
  • KFY N/A
  • Revenue Next Year
  • SRRK N/A
  • KFY $5.40
  • P/E Ratio
  • SRRK N/A
  • KFY $15.14
  • Revenue Growth
  • SRRK N/A
  • KFY N/A
  • 52 Week Low
  • SRRK $6.76
  • KFY $55.27
  • 52 Week High
  • SRRK $46.19
  • KFY $80.64
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 57.37
  • KFY 57.31
  • Support Level
  • SRRK $38.72
  • KFY $64.52
  • Resistance Level
  • SRRK $45.15
  • KFY $68.65
  • Average True Range (ATR)
  • SRRK 2.33
  • KFY 1.49
  • MACD
  • SRRK -0.32
  • KFY 0.68
  • Stochastic Oscillator
  • SRRK 73.28
  • KFY 98.81

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About KFY Korn Ferry

Korn Ferry is a United States-based firm engaged in organizational consulting and management recruitment that helps clients fill mid- to high-level management positions. The company's segment includes Consulting; Digital; Executive Search; Professional Search & Interim; and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The consulting segment aligns organizational structure, culture, performance, development, and people to drive sustainable growth by addressing four fundamental organizational and talent needs. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.

Share on Social Networks: